z-logo
open-access-imgOpen Access
Expression of Stat3 and Notch1 is associated with cisplatin resistance in head and neck squamous cell carcinoma
Author(s) -
Feng Gu,
Yongjie Ma,
Zuping Zhang,
Jinghui Zhao,
Hisayuki Kobayashi,
Lun Zhang,
Li Fu
Publication year - 2010
Publication title -
oncology reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.094
H-Index - 96
eISSN - 1791-2431
pISSN - 1021-335X
DOI - 10.3892/or_00000683
Subject(s) - cisplatin , head and neck squamous cell carcinoma , cancer research , oncogene , cell cycle , head and neck cancer , stat3 , oncology , cell , chemotherapy , molecular medicine , apoptosis , biology , medicine , cancer , biochemistry , genetics
Cisplatin is the most important chemotherapeutic agent involved in treatment of head and neck squamous cell carcinoma (HNSCC), but cisplatin resistance in HNSCC is still a serious problem in clinic. The reasons why patients fail chemotherapy are unclear. We examined 25 HNSCC patients who were all tested for cisplatin sensitivity by CD-DST (collagen gel droplet embedded culture-drug sensitivity) method and expression of Stat3 and Notch1. We found that high expression levels of Stat3 and Notch1 were closely associated with cisplatin resistance respectively (P=0.014, P=0.000). In addition, cisplatin resistance of HNSCC was decreased after inhibition of Stat3 or Notch signaling in vitro. Our results provide first evidence that both high Stat3 and Notch1 expression are associated with cisplatin resistance in HNSCC patients, supporting the hypothesis that co-activation of Stat3 and Notch1 by their crosstalk induces the reprogrammed survival pathways in HNSCC responding to chemotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom